Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 230

Sort by

Sort Order Select

Journal Articles

Reduced Iron Overload with Pegcetacoplan Treatment in Eculizumab-Experienced Patients with Paroxysmal Nocturnal Hemoglobinuria

Jamile Shammo, Michael Yeh, Peter Hillmen, David J Kuter

Blood (2024) 144 (Supplement 1): 5677.

https://doi.org/10.1182/blood-2024-203271

Published: 2024

Journal Articles

Real-World Adherence with Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria Compared with Previously Reported Oral Medication Adherence Rates

David Dingli, Brian Mulherin, Peter Hillmen, Barbara Czech, Jens Panse

Blood (2024) 144 (Supplement 1): 5680.

https://doi.org/10.1182/blood-2024-203541

Published: 2024

Journal Articles

Thrombosis and Encapsulated Bacterial Infection Rates in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Received Pegcetacoplan: Nearly 3 Years of Post-Marketing Experience

Gloria F. Gerber, Richard J. Kelly, Hisakazu Nishimori, Regina Horneff, Peter Hillmen, Uchendu O. Uchendu, Yiwei Zhang, Stacie Lallier, Jens Panse

Blood (2024) 144 (Supplement 1): 5698.

https://doi.org/10.1182/blood-2024-201443

Published: 2024

Journal Articles

IGHV Unmutated Status, Low Tumor Lysis Risk Disease and BRAF Mutated Status Are Predictors for Early MRD Responders Treated with MRD Defined Ibrutinib with Venetoclax: Report of the UK NCRI FLAIR Study

Blood (2024) 144 (Supplement 1): 585.

https://doi.org/10.1182/blood-2024-211449

Published: 2024

Journal Articles

Telomere Length and DNA Methylation Epitype Both Provide Independent Prognostic Information in CLL Patients; Data from the UK CLL4, Arctic and Admire Clinical Trials

Louise J. Carr, Kevin Norris, Helen Parker, Anna Nilsson-Takeuchi, Dean J. Bryant, Harindra Eranthi Amarasinghe, Latha Kadalayil, Monica Else, Tomasz Wojdacz, Andrew Pettitt, Peter Hillmen, Anna Schuh, Renata Walewska, Duncan M. Baird, David Graham Oscier, Christopher C. Oakes, Jane Gibson, Chris Pepper, Jonathan C. Strefford

Blood (2023) 142 (Supplement 1): 6514.

https://doi.org/10.1182/blood-2023-177575

Published: 2023

Journal Articles

Paroxysmal Nocturnal Haemoglobinuria (PNH) Arising from Non-Canonical Mutations

Alexandra Pike, Stephen John Richards, Claire E McKinley, Louise M Arnold, Abraham Mullasseril Varghese, Talha Munir, Petra Muus, Peter Hillmen, Morag Griffin, Richard J Kelly, Darren Newton

Blood (2023) 142 (Supplement 1): 4097.

https://doi.org/10.1182/blood-2023-188755

Published: 2023

Journal Articles

Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial

Andy Rawstron, Nichola Webster, Surita Dalal, Ruth M de Tute, Sue Bell, David Allan Cairns, Sean Girvan, Natasha Greatorex, Anna Hockaday, Sharon Jackson, David Phillips, David Stones, David Allsup, Adrian John Clifton Bloor, Anita Sarma, Abraham Mullasseril Varghese, Talha Munir, Peter Hillmen

Blood (2023) 142 (Supplement 1): 632.

https://doi.org/10.1182/blood-2023-187943

Published: 2023

Journal Articles

Ibrutinib and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab for Patients in NCRI FLAIR Study with Previously Untreated CLL: Assessment of Mutational Landscape of Patients at Baseline and Prognostic Impact

Blood (2023) 142 (Supplement 1): 4637.

https://doi.org/10.1182/blood-2023-180527

Published: 2023

Journal Articles

Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study

Blood (2023) 142 (Supplement 1): 631.

https://doi.org/10.1182/blood-2023-178298

Published: 2023

Journal Articles

Molecular Analysis at Relapse of Patients Treated on the Ibrutinib and Rituximab Arm of the National Multi-Centre Phase III FLAIR Study in Previously Untreated CLL Patients

Blood (2023) 142 (Supplement 1): 4636.

https://doi.org/10.1182/blood-2023-188597

Published: 2023

Journal Articles

Sars-Cov-2 Antibody and T-Cell Responses in Patients with Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia after Four COVID-19 Vaccinations

Blood (2023) 142 (Supplement 1): 2712.

https://doi.org/10.1182/blood-2023-190393

Published: 2023

Journal Articles

Efficacy and Safety Is Maintained in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan for up to 3 Years

Carlos M de Castro, Brian Mulherin, Christopher J. Patriquin, Veena Selvaratnam, Raymond SM Wong, Richard J. Kelly, Lisa Tan, Peter Hillmen, Dale Zhang, Jessica Savage, Regis Peffault De Latour

Blood (2023) 142 (Supplement 1): 574.

https://doi.org/10.1182/blood-2023-181054

Published: 2023

Journal Articles

Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study

Blood (2022) 140 (Supplement 2): LBA-6.

https://doi.org/10.1182/blood-2022-171538

Published: 2022

Journal Articles

MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study

Blood (2022) 140 (Supplement 1): 222–223.

https://doi.org/10.1182/blood-2022-166700

Published: 2022

Journal Articles

Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study

Blood (2022) 140 (Supplement 1): 231–233.

https://doi.org/10.1182/blood-2022-170463

Published: 2022

Journal Articles

High-Sensitivity Analysis of Normal B-Cell Subsets in MBL and Untreated CLL Identifies Patients with Sub-Optimal Sars-Cov-2 Antibody Responses

Andrew C. Rawstron, James Senior, Nichola Webster, Vicky Martin, Ruth M. de Tute, Talha Munir, Peter Hillmen

Blood (2022) 140 (Supplement 1): 7032–7033.

https://doi.org/10.1182/blood-2022-170945

Published: 2022

Journal Articles

SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab (BR) in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Blood (2021) 138 (Supplement 1): 396.

https://doi.org/10.1182/blood-2021-148457

Published: 2021

Journal Articles

Sudden or Cardiac Deaths on Ibrutinib-Based Therapy Were Associated with a Prior History of Hypertension or Cardiac Disease and the Use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial

Blood (2021) 138 (Supplement 1): 2636.

https://doi.org/10.1182/blood-2021-152167

Published: 2021

Journal Articles

Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Early Results from Arm D of the SEQUOIA (BGB-3111-304) Trial

Alessandra Tedeschi, Emmanuelle Ferrant, Ian W. Flinn, Constantine S. Tam, Paolo Ghia, Tadeusz Robak, Jennifer R. Brown, Vanitha Ramakrishnan, Tian Tian, Sowmya B. Kuwahara, Jason C. Paik, Aileen Cohen, Jane Huang, Peter Hillmen

Blood (2021) 138 (Supplement 1): 67.

https://doi.org/10.1182/blood-2021-144336

Published: 2021

Journal Articles

Characterization of Bruton Tyrosine Kinase Inhibitor (BTKi)-Related Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)

John F. Seymour, John C. Byrd, Peter Hillmen, Paolo Ghia, Arnon P. Kater, Asher Chanan-Khan, Richard Furman, Susan M. O'Brien, Jennifer R Brown, Anthony R. Mato, Stephan Stilgenbauer, Nataliya Kuptsova-Clarkson, Paulo Miranda, Dennis Wagner, Kara Higgins, Sophia Sohoni, Wojciech Jurczak

Blood (2021) 138 (Supplement 1): 3721.

https://doi.org/10.1182/blood-2021-146228

Published: 2021

NARROW

Reduced Iron Overload with Pegcetacoplan Treatment in Eculizumab-Experienced Patients with Paroxysmal Nocturnal Hemoglobinuria

Real-World Adherence with Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria Compared with Previously Reported Oral Medication Adherence Rates

Thrombosis and Encapsulated Bacterial Infection Rates in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Received Pegcetacoplan: Nearly 3 Years of Post-Marketing Experience

IGHV Unmutated Status, Low Tumor Lysis Risk Disease and BRAF Mutated Status Are Predictors for Early MRD Responders Treated with MRD Defined Ibrutinib with Venetoclax: Report of the UK NCRI FLAIR Study

Telomere Length and DNA Methylation Epitype Both Provide Independent Prognostic Information in CLL Patients; Data from the UK CLL4, Arctic and Admire Clinical Trials

Paroxysmal Nocturnal Haemoglobinuria (PNH) Arising from Non-Canonical Mutations

Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial

Ibrutinib and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab for Patients in NCRI FLAIR Study with Previously Untreated CLL: Assessment of Mutational Landscape of Patients at Baseline and Prognostic Impact

Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study

Molecular Analysis at Relapse of Patients Treated on the Ibrutinib and Rituximab Arm of the National Multi-Centre Phase III FLAIR Study in Previously Untreated CLL Patients

Sars-Cov-2 Antibody and T-Cell Responses in Patients with Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia after Four COVID-19 Vaccinations

Efficacy and Safety Is Maintained in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan for up to 3 Years

Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study

MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study

Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study

High-Sensitivity Analysis of Normal B-Cell Subsets in MBL and Untreated CLL Identifies Patients with Sub-Optimal Sars-Cov-2 Antibody Responses

SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab (BR) in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Sudden or Cardiac Deaths on Ibrutinib-Based Therapy Were Associated with a Prior History of Hypertension or Cardiac Disease and the Use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial

Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Early Results from Arm D of the SEQUOIA (BGB-3111-304) Trial

Characterization of Bruton Tyrosine Kinase Inhibitor (BTKi)-Related Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only